A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
Sponsor: Hutchmed
Terminated
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns
Other terminated trials from Hutchmed
Other Isocitrate Dehydrogenase Gene Mutation trials with similar outcome
This PHASE1 trial investigates Isocitrate Dehydrogenase Gene Mutation and is currently terminated or withdrawn. Hutchmed leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
-
May 2025 — Feb 2026 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jun 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hutchmed
For direct contact, visit the study record on ClinicalTrials.gov .